| Forward Counseling And Consultation Llc | |
|
2000 Engel St Ste 201 Monona WI 53713-4822 | |
| (608) 455-6070 | |
| (608) 455-0883 |
| Full Name | Forward Counseling And Consultation Llc |
|---|---|
| Speciality | Counselor |
| Location | 2000 Engel St Ste 201, Monona, Wisconsin |
| Authorized Official Name and Position | Michelle Murray (PSYCHOTHERAPIST/COFOUNDER) |
| Authorized Official Contact | 6084556070 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Forward Counseling And Consultation Llc 2000 Engel St Ste 201 Monona WI 53713-4822 Ph: (608) 455-6070 | Forward Counseling And Consultation Llc 2000 Engel St Ste 201 Monona WI 53713-4822 Ph: (608) 455-6070 |
| NPI Number | 1487192928 |
|---|---|
| Provider Enumeration Date | 02/04/2017 |
| Last Update Date | 08/03/2023 |
| Certification Date | 08/03/2023 |
| Medicare PECOS PAC ID | 0042668709 |
|---|---|
| Medicare Enrollment ID | O20231120000739 |
News Archive
A new study suggests that the evolution of antibiotic tolerance requires further investigation if newly designed antibiotic treatments are going to be able to prevent drug-resistant infections.
As student athletes prepare to return to school, it's crucial they wear protective gear, like mouthguards, even when playing sports not usually associated with contact. A properly fitted mouthguard can help save your child's smile and keep them off the injured list.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487192928 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Provider Name | Amanda M Henschel |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1336659770 PECOS PAC ID: 3971866567 Enrollment ID: I20180412001864 |
News Archive
A new study suggests that the evolution of antibiotic tolerance requires further investigation if newly designed antibiotic treatments are going to be able to prevent drug-resistant infections.
As student athletes prepare to return to school, it's crucial they wear protective gear, like mouthguards, even when playing sports not usually associated with contact. A properly fitted mouthguard can help save your child's smile and keep them off the injured list.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
› Verified 3 days ago
| Provider Name | Jacob M Schuldies |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1780843078 PECOS PAC ID: 0648600676 Enrollment ID: I20200415001491 |
News Archive
A new study suggests that the evolution of antibiotic tolerance requires further investigation if newly designed antibiotic treatments are going to be able to prevent drug-resistant infections.
As student athletes prepare to return to school, it's crucial they wear protective gear, like mouthguards, even when playing sports not usually associated with contact. A properly fitted mouthguard can help save your child's smile and keep them off the injured list.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
› Verified 3 days ago
News Archive
A new study suggests that the evolution of antibiotic tolerance requires further investigation if newly designed antibiotic treatments are going to be able to prevent drug-resistant infections.
As student athletes prepare to return to school, it's crucial they wear protective gear, like mouthguards, even when playing sports not usually associated with contact. A properly fitted mouthguard can help save your child's smile and keep them off the injured list.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
› Verified 3 days ago
Yahara Counseling Center, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6320 Monona Dr Ste 408, Monona, WI 53716 Phone: 608-467-9074 Fax: 608-467-9075 | |
Kaitlyn Laurie, S.c Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6320 Monona Dr, Monona, WI 53716 Phone: 608-235-3546 | |
Day Treatment-madison Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5900 Monona Dr Ste 200, Monona, WI 53716 Phone: 608-223-3323 | |
Center For Life & Loss Integration Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4123 Monona Dr, Monona, WI 53716 Phone: 608-258-7771 Fax: 608-832-6486 | |
Monona Mediation And Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6320 Monona Dr Ste 314, Monona, WI 53716 Phone: 608-442-3420 Fax: 608-443-3421 | |
Bemis Psychotherapy And Consulting, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5900 Monona Dr Ste 313, Monona, WI 53716 Phone: 608-514-1764 | |
Day One Mental Health Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1955 W Broadway Ste 101, Monona, WI 53713 Phone: 608-895-2716 |